Effect of metformin and empagliflozin on adiponectin and leptin levels in rat model of hypo- and hyperthyroidism

References

• Krotkiewski M. Thyroid hormones in the pathogenesis and treatment of obesity. Eur J Pharmacol. 2002; 440(2–3):85–98.
   PubMed Web of Science ®Google Scholar
• Sahzene Y, Salgado S, del Prado N. Thyroid HormoneAction and Energy Expenditure. J Endocr Soc. 2019; 3(7):410.
   Web of Science ®Google Scholar
• Ambrosi B, Masserini B, Iorio L, et al. Relationship of thyroid function with body mass index and insulin-resistance in euthyroid obese subjects. J Endocrinol Invest. 2010; 33(9):640–643.
   PubMed Web of Science ®Google Scholar
• Xu R, Huang F, Zhang S, et al., Thyroid function, body mass index, and metabolic risk markers in euthyroid adults: a cohort study. BMC Endocr Disord. 2019; 19(1):58.
   PubMedGoogle Scholar
• Choe SS, Huh JY, Hwang IJ, et al. Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. Front Endocrinol (Lausanne)). 2016;7:30.
   PubMed Web of Science ®Google Scholar
• Harris RB. Direct and indirect effects of leptin on adipocyte metabolism. Biochim Biophys Acta. 2014;1842(3):414–423.
   PubMed Web of Science ®Google Scholar
• Zimmermann-Belsing T, Brabant G, Holst JJ, et al. Circulating leptin and thyroid dysfunction. Eur J Endocrinol. 2003;149(4):257–271.
   PubMed Web of Science ®Google Scholar
• Lancha A, Fruhbeck G, Gomez-Ambrosi J. Peripheral signalling involved in energy homeostasis control. Nutr Res Rev. 2012;25(2):223–248.
   PubMed Web of Science ®Google Scholar
• Delitala AP, Steri M, Fiorillo E, et al. Adipocytokine correlations with thyroid function and autoimmunity in euthyroid sardinians. Cytokine. 2018;111:189–193.
   PubMed Web of Science ®Google Scholar
• Aydogan BI, Sahin M. Adipocytokines in thyroid dysfunction. ISRN Inflamm, 2013. p. 646271.
   Google Scholar
• Farcaş AD, Rusu A, Stoia MA, et al. Plasma leptin, but not resistin, TNF-alpha and adiponectin, is associated with echocardiographic parameters of cardiac remodeling in patients with coronary artery disease. Cytokine. 2018;103:46–49.
   PubMed Web of Science ®Google Scholar
• Delitala AP, Scuteri A, Fiorillo E. Role of Adipokines in the Association between Thyroid Hormone and Components of the Metabolic Syndrome. J Clin Med. 2019; 8(6).
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin Ratio is a Functional Biomarker of Adipose Tissue Inflammation. Nutrients. 2019;11(2):454.
   PubMed Web of Science ®Google Scholar
• van Tienhoven-Wind LJ, Dullaart RP. Increased leptin/adiponectin ratio relates to low-normal thyroid function in metabolic syndrome. Lipids Health Dis. 2017;16(1):6.
   PubMedGoogle Scholar
• Gasbarrino K, Gorgui J, Nauche B, et al. Circulating adiponectin and carotid intima-media thickness: a systematic review and meta-analysis. Metabolism. 2016;65(7):966–968.
   Web of Science ®Google Scholar
• Calvino C, Império GE, Wilieman M, et al. Hypothyroidism induces hypophagia associated with alterations in protein expression of neuropeptide y and proopiomelanocortin in the arcuate nucleus, independently of hypothalamic nuclei-specific changes in leptin signaling. Thyroid. 2016;26(1):134–143.
   PubMed Web of Science ®Google Scholar
• Bagepally BS, Chaikledkaew U, Gurav YK. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Res Care. 2020; 8(1).
   PubMed Web of Science ®Google Scholar
• Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia. 2017; 60(2):364–376.
   PubMed Web of Science ®Google Scholar
• Vickers SP, Cheetham SC, Headland KR, et al. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes. 2014;7:265–275.
   PubMedGoogle Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7(1):57–62.
   PubMed Web of Science ®Google Scholar
• Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie. 2012;94(10):2143–2149.
   PubMed Web of Science ®Google Scholar
• Zaletel J, Barlovic DP, Prezelj J. Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with Type 2 diabetes. J Endocrinol Invest. 2010;33(8):514–518.
   PubMed Web of Science ®Google Scholar
• Inoue M, Maehata E, Yano M, et al. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism. 2005;54(3):281–286.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12(2):90–100.
   PubMed Web of Science ®Google Scholar
• Gong N, Gao C, Chen X, et al. Adipokine expression and endothelial function in subclinical hypothyroidism rats. Endocr Connect. 2018;7(2):295–304.
   PubMed Web of Science ®Google Scholar
• Syed MA, Thompson MP, Pachucki J, et al. The effect of thyroid hormone on size of fat depots accounts for most of the changes in leptin mRNA and serum levels in the rat. Thyroid. 1999;9(5):503–512.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Escobar del Rey F, Morreale de Escobar G. Thyroid hormones influence serum leptin concentrations in the rat. Endocrinology. 1997;138(10):4485–4488.
   PubMed Web of Science ®Google Scholar
• Iglesias P, Alvarez Fidalgo P, Codoceo R, et al. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf). 2003;59(5):621–629.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012;94(10):2137–2142.
   PubMed Web of Science ®Google Scholar
• Sorisky A, Bell A, Gagnon A. TSH receptor in adipose cells. Horm Metab Res. 2000;32(11–12):468–474.
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Chen G, et al. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diabetes Res Care. 2019;7(1):e000783–142.
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149.
   PubMed Web of Science ®Google Scholar